Trading Halt
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Lumos Diagnostics Holdings Limited has requested a trading halt for its securities on the Australian Securities Exchange pending an announcement regarding the FDA response to the FebriDx CLIA waiver application. The halt will remain in effect until normal trading resumes or the announcement is made, expected before the end of the trading week. This request is made to assist the company in managing its continuous disclosure obligations.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-475
Watch Lumos Diagnostics' latest callLumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call · Replay · Apr 20Read the transcript of Lumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings CallLumos Diagnostics Holdings Ltd. on 6ix
In the deck
Earlier from Lumos Diagnostics
- Lumos Delivers Several Pivotal Milestones in 1H FY26
- Appendix 4D and Half Year Report
- Lumos Completes Enrolment Milestone for Paediatric Study
- Quarterly Activities/Appendix 4C Cash Flow Report
- Lumos Secures 100% US Medicare Reimbursement for FebriDx
Later from Lumos Diagnostics
- US FDA Grants CLIA Waiver for FebriDx
- Lumos completes $20m placement and launches SPP
- Investor Presentation
- Lumos receives largest FebriDx order to date
- Lumos secures new contract manufacturing agreement
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics